TY - JOUR
T1 - Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia
AU - Fujimoto, Ayumi
AU - Ishida, Fumihiro
AU - Izutsu, Koji
AU - Yamasaki, Satoshi
AU - Chihara, Dai
AU - Suzumiya, Junji
AU - Mitsui, Tetsuo
AU - Doki, Noriko
AU - Sakai, Hitoshi
AU - Kobayashi, Hikaru
AU - Kanda, Junya
AU - Fukuda, Takahiro
AU - Atsuta, Yoshiko
AU - Suzuki, Ritsuro
N1 - Funding Information:
Acknowledgements We thank all the physicians and data managers at the centers who contributed to gathering data on transplantation for the Transplant Registry Unified Management Program and all the members of the Data Management Committees of Japan Society for Hematopoietic Cell Transplantation. This work was supported in part by the Practical Research Project for Allergic Disease and Immunology (Research Technology of Medical Transplantation), Japan Agency for Medical Research and Development, AMED.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Aggressive NK-cell leukemia (ANKL) has a fulminant clinical course with a poor prognosis. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment. Using the Japanese transplant registry data, the outcomes of 59 ANKL patients who underwent first allo-HSCT were analyzed. Twenty-nine patients received stem cells from cord blood (CB), 18 from peripheral blood, and 12 from bone marrow. At the time of transplant 21 patients had complete response (CR), and 7 partial response (PR), but 31 without response. The 1-year and 5-year overall survival (OS) were 33.9% and 27.3%, respectively. The 1-year cumulative incidences of relapse or progression was 55.5%, and that of non-relapse mortality was 12.1%. The OS was significantly better for patients with CR or PR at the time of allo-HSCT (P = 0.046), which was equivalent to that for patients who experienced primary induction failure at the time of allo-HSCT but achieved CR afterwards (40.6% versus 32.0% at 5 years; P = 0.95). Patients receiving CB had a significantly better OS than those receiving stem cells from others (37.3% versus 16.2% at 5 years; P = 0.04). Patients achieving event-free survival at 12 months after allo-HSCT had good outcomes with 5-year OS of 85.2%.
AB - Aggressive NK-cell leukemia (ANKL) has a fulminant clinical course with a poor prognosis. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment. Using the Japanese transplant registry data, the outcomes of 59 ANKL patients who underwent first allo-HSCT were analyzed. Twenty-nine patients received stem cells from cord blood (CB), 18 from peripheral blood, and 12 from bone marrow. At the time of transplant 21 patients had complete response (CR), and 7 partial response (PR), but 31 without response. The 1-year and 5-year overall survival (OS) were 33.9% and 27.3%, respectively. The 1-year cumulative incidences of relapse or progression was 55.5%, and that of non-relapse mortality was 12.1%. The OS was significantly better for patients with CR or PR at the time of allo-HSCT (P = 0.046), which was equivalent to that for patients who experienced primary induction failure at the time of allo-HSCT but achieved CR afterwards (40.6% versus 32.0% at 5 years; P = 0.95). Patients receiving CB had a significantly better OS than those receiving stem cells from others (37.3% versus 16.2% at 5 years; P = 0.04). Patients achieving event-free survival at 12 months after allo-HSCT had good outcomes with 5-year OS of 85.2%.
UR - http://www.scopus.com/inward/record.url?scp=85089255290&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089255290&partnerID=8YFLogxK
U2 - 10.1038/s41409-020-01009-8
DO - 10.1038/s41409-020-01009-8
M3 - Article
C2 - 32778688
AN - SCOPUS:85089255290
SN - 0268-3369
VL - 56
SP - 347
EP - 356
JO - Bone marrow transplantation
JF - Bone marrow transplantation
IS - 2
ER -